Specific Phobia Clinical Trial
Official title:
Use of Safety Behaviors in Exposure Therapy for Arachnophobia
Verified date | October 2021 |
Source | University of Nevada, Reno |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study examines the impact of safety behaviors (i.e., unnecessary protective actions) on outcomes of exposure therapy for spider phobia. Researchers will compare exposure therapy with (a) no safety behaviors, (b) safety behaviors faded toward the end of treatment, and (c) unfaded safety behaviors.
Status | Completed |
Enrollment | 59 |
Est. completion date | April 6, 2020 |
Est. primary completion date | April 6, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Fluent in English - Displays sufficiently high fear of spiders, as indicated by responses on (a) a self report questionnaire (the Fear of Spiders Questionnaire) at prescreening, and (b) Behavioral Avoidance Tests at baseline Exclusion Criteria: - younger than 18 years old |
Country | Name | City | State |
---|---|---|---|
United States | University of Nevada, Reno | Reno | Nevada |
Lead Sponsor | Collaborator |
---|---|
University of Nevada, Reno |
United States,
Deacon BJ, Sy JT, Lickel JJ, Nelson EA. Does the judicious use of safety behaviors improve the efficacy and acceptability of exposure therapy for claustrophobic fear? J Behav Ther Exp Psychiatry. 2010 Mar;41(1):71-80. doi: 10.1016/j.jbtep.2009.10.004. Epub 2009 Oct 24. — View Citation
Powers MB, Smits JA, Telch MJ. Disentangling the effects of safety-behavior utilization and safety-behavior availability during exposure-based treatment: a placebo-controlled trial. J Consult Clin Psychol. 2004 Jun;72(3):448-54. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Behavioral approach test (treatment context) - behavioral outcome | Participants will approach a live, non-poisonous tarantula, placed on the floor, at the opposite end of the room. The participant will walk toward the spider during this test. The test is over when the participant has reached the hardest step that they can complete at that time.
During this BAT, investigators will assess fear response behaviorally by recording the most challenging step completed (range, steps 0 -12). |
Change from baseline up to 4 weeks later (through follow up assessment) | |
Primary | Behavioral approach test (treatment context) - subjective outcome | Participants will approach a live, non-poisonous tarantula, placed on the floor, at the opposite end of the room. The participant will walk toward the spider during this test. The test is over when the participant has reached the hardest step that they can complete at that time.
During this BAT, investigators will assess fear response subjectively by having participants self report their peak fear level (on a 0 to 100 scale). |
Change from baseline up to 4 weeks later (through follow up assessment) | |
Primary | Behavioral approach test (treatment context) - physiological outcome | Participants will approach a live, non-poisonous tarantula, placed on the floor, at the opposite end of the room. The participant will walk toward the spider during this test. The test is over when the participant has reached the hardest step that they can complete at that time.
During this BAT, investigators will assess fear response physiologically by assessing heart rate variability. |
Change from baseline up to 4 weeks later (through follow up assessment) | |
Primary | Behavioral approach test (generalization context) - behavioral outcome | Participants will approach a live, non-poisonous tarantula, placed in a clear tank on a table, at the opposite end of the room. The test is over when the participant has reached the hardest step that they can complete at that time. Steps include walking toward the spider and lowering one hand into the tank.
During this BAT, investigators will assess fear response behaviorally by recording the most challenging step completed (range, steps 0-21). |
Change from baseline up to 4 weeks later (through follow up assessment) | |
Primary | Behavioral approach test (generalization context) - subjective outcome | Participants will approach a live, non-poisonous tarantula, placed in a clear tank on a table, at the opposite end of the room. The test is over when the participant has reached the hardest step that they can complete at that time. Steps include walking toward the spider and lowering one hand into the tank.
During this BAT, investigators will assess fear response subjectively by having participants self report their peak fear level (on a 0 to 100 scale). |
Change from baseline up to 4 weeks later (through follow up assessment) | |
Primary | Behavioral approach test (generalization context) - physiological outcome | Participants will approach a live, non-poisonous tarantula, placed in a clear tank on a table, at the opposite end of the room. The test is over when the participant has reached the hardest step that they can complete at that time. Steps include walking toward the spider and lowering one hand into the tank.
During this BAT, investigators will assess fear response physiologically by assessing heart rate variability. |
Change from baseline up to 4 weeks later (through follow up assessment) | |
Primary | Fear of Spiders Questionnaire (FSQ) | Self-report rating scale in which participants rate the extent that they agree with a number of statements that are representative of having a fear of spiders. Sum total scores will be calculated (range 0-108). Higher scores indicate more severe symptom levels. | Change from baseline up to 4 weeks later (through follow up assessment) | |
Primary | Spider Phobia Beliefs Questionnaire (SBQ) | Self-report rating scale assessing the level to which the participant believes a number of cognitions/thoughts commonly associated with spider phobia. An overall average rating will be calculated (range 0-100). Higher average scores indicate greater belief in spider phobic cognitions. | Change from baseline up to 4 weeks later (through follow up assessment) | |
Primary | Armfield and Mattiske Disgust Questionnaire (AMDQ) | Self-report questionnaire assessing feelings of disgust associated with spiders. Sum total scores will be calculated (range 0-48). Higher scores indicate more severe spider-related disgust. | Change from baseline up to 4 weeks later (through follow up assessment) | |
Primary | Anxiety Disorders Interview Schedule for DSM-5 (ADIS-5) | Participants will be given a structured interview to identify whether they meet diagnostic criteria for specific phobia. Responses will be coded dichotomously (yes = has diagnosis; no = no diagnosis). | Change from baseline up to 4 weeks later (through follow up assessment) | |
Secondary | Treatment Acceptability/Adherence Scale (Modified version) | Self-report questionnaire assessing the participant's perceptions regarding treatment acceptability and willingness to adhere to treatment procedures. Sum total scores will be calculated (range 10-70). Higher scores indicate greater acceptability/adherence. | Measured just prior to beginning a one-session treatment | |
Secondary | Treatment Acceptability/Adherence Scale (Modified version) | Self-report questionnaire assessing the participant's perceptions regarding treatment acceptability and willingness to adhere to treatment procedures. Sum total scores will be calculated (range 10-70). Higher scores indicate greater acceptability/adherence. | Measured immediately after completing a one-session treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04594525 -
Maternal Telemental Health Interventions in Response to Covid-19*
|
N/A | |
Completed |
NCT02306356 -
Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting
|
N/A | |
Completed |
NCT03233113 -
The Effects of Safety Seeking Behaviors During Exposure Therapy for Adults With Spider Phobia
|
N/A | |
Completed |
NCT04504773 -
Using Immersive Virtual Reality to Treat Pediatric Anxiety
|
N/A | |
Completed |
NCT05300061 -
Values Interventions for Increasing Engagement With What is Feared in Individuals With Specific Phobias
|
N/A | |
Completed |
NCT03208400 -
Virtual Reality Exposure in Spider Phobia
|
N/A | |
Completed |
NCT03688373 -
Facing Fears in Big or Smalls Steps?
|
N/A | |
Completed |
NCT03688360 -
Facing Fears In-session or Out-session?
|
N/A | |
Recruiting |
NCT02305537 -
Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
|
N/A | |
Terminated |
NCT03764644 -
Web-based Attention Bias Modification Treatment for Childhood Anxiety Disorders
|
N/A | |
Terminated |
NCT01979263 -
Attention Bias Modification Treatment for Anxious Youth
|
N/A | |
Not yet recruiting |
NCT02972112 -
Ultrashort Cognitive Behavioral Intervention for Tokophobia- A Prospective Randomized Single Blinded Controlled Trial
|
N/A | |
Completed |
NCT02554838 -
How to Act on the Mobility Restriction Linked to Senior's Phobia of Falling
|
N/A | |
Completed |
NCT01491880 -
Treatment Study for Rural Latino Youth With Anxiety
|
Phase 1/Phase 2 | |
Completed |
NCT01947647 -
Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders
|
N/A | |
Recruiting |
NCT04563390 -
Effectiveness of a Projection-based Augmented Reality Exposure System in Treating Cockroach Phobia.
|
N/A | |
Completed |
NCT05284435 -
Internet-Based, Parent-Led Cognitive-Behavioral Therapy for Anxiety in Youth With ASD
|
N/A | |
Completed |
NCT03105024 -
Self-efficacy Enhancement and Exposure Therapy
|
N/A | |
Completed |
NCT01923896 -
D-cycloserine and Treatment of Feeding Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT03917550 -
RECOVERY: A Transdiagnostic Intervention for Anxiety and Depression
|
N/A |